These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39254698)

  • 1. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
    Katzdobler S; Nübling G; Klietz M; Fietzek UM; Palleis C; Bernhardt AM; Wegner F; Huber M; Rogozinski S; Schneider LS; Spruth EJ; Beyle A; Vogt IR; Brandt M; Hansen N; Glanz W; Brockmann K; Spottke A; Hoffmann DC; Peters O; Priller J; Wiltfang J; Düzel E; Schneider A; Falkenburger B; Klockgether T; Gasser T; Nuscher B; Haass C; Höglinger G; Levin J
    J Neurol; 2024 Oct; 271(10):6991-6999. PubMed ID: 39254698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study.
    Singer W; Schmeichel AM; Sletten DM; Gehrking TL; Gehrking JA; Trejo-Lopez J; Suarez MD; Anderson JK; Bass PH; Lesnick TG; Low PA
    Clin Auton Res; 2023 Dec; 33(6):635-645. PubMed ID: 37603107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
    Hu X; Yang Y; Gong D
    Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy.
    Santaella A; Kuiperij HB; van Rumund A; Esselink RAJ; Bloem BR; Verbeek MM
    Parkinsonism Relat Disord; 2020 Jul; 76():80-84. PubMed ID: 32576494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
    Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij HB; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
    Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
    Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
    Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
    Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
    Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders.
    Dobson H; Al Maawali S; Malpas C; Santillo AF; Kang M; Todaro M; Watson R; Yassi N; Blennow K; Zetterberg H; Foster E; Neal A; Velakoulis D; O'Brien TJ; Eratne D; Kwan P
    Epilepsia; 2024 Sep; 65(9):2751-2763. PubMed ID: 39032019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt-Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia.
    Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Rossi M; Polischi B; Capellari S; Parchi P
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study.
    Peng L; Wan L; Liu M; Long Z; Chen D; Yuan X; Tang Z; Fu Y; Zhu S; Lei L; Wang C; Peng H; Shi Y; He L; Yuan H; Wan N; Hou X; Xia K; Li J; Chen C; Qiu R; Tang B; Chen Z; Jiang H
    J Neurol; 2023 Sep; 270(9):4248-4261. PubMed ID: 37184660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
    Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
    Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
    Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
    Alzheimers Res Ther; 2024 Jul; 16(1):165. PubMed ID: 39054505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.